Clinical Trials Brief — November 12, 2026
Summary for November 12, 2026. adaptive_design : sponsor Current Sentiment: Cautious or mixed sentiment with some intensity Eli Lilly implemented adaptive platform designs in Alzheimer’s trials to allow seamless phase transitions, discussed in recent scientific publications and industry webinars. Alternative view: Increased operational complexity raises risks of biased interim analyses if not rigorously controlled. vaccine_development